Aprea Therapeutics (APRE) risk factors

77 risks, 7 new, 5 dropped, 9 reworded since the prior year. Aprea faces clinical trial pauses for ABOYA-119 and ATRN-119, a Nasdaq delisting threat over low share prices, and expanding net deferred tax asset valuations.

75 risks. Aprea Therapeutics faces ongoing net losses with an accumulated deficit of $321.0 million and substantial doubt regarding its going concern status. The company relies heavily on a single contract manufacturer for active pharmaceutical ingredients without redundant supply arrangements. Patent protection depends largely on method-of-use and formulation claims rather than composition-of-matter patents for the API.